594
Participants
Start Date
June 30, 2012
Primary Completion Date
November 30, 2015
Study Completion Date
November 30, 2015
Maraviroc
300-mg tablet, once daily, from Week 0 through Week 48
Emtricitabine
200-mg capsule, once daily, from Week 0 through Week 48
Tenofovir disoproxil fumarate
300-mg tablet, once daily, from Week 0 through Week 48
Maraviroc placebo
Once daily from Week 0 through Week 48
Emtricitabine placebo
Once daily from Week 0 through Week 48
Tenofovir disoproxil fumarate placebo
Once daily from Week 0 through Week 48
Weill Cornell Chelsea CRS, New York
University of Pittsburgh CRS, Pittsburgh
Penn Therapeutics, CRS, Philadelphia
George Washington Univ. CRS, Washington D.C.
Johns Hopkins University CRS, Baltimore
Chapel Hill CRS, Chapel Hill
Case Clinical Research Site, Cleveland
UCLA CARE Center CRS, Los Angeles
Bridge HIV CRS, San Francisco
Fenway Health (FH) CRS, Boston
New Jersey Medical School Clinical Research Center CRS, Newark
University of Washington AIDS CRS, Seattle
Puerto Rico AIDS Clinical Trials Unit CRS, San Juan
HIV Prevention Trials Network
NETWORK
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK
National Institute of Allergy and Infectious Diseases (NIAID)
NIH